US20050277764A1 - Mammalian mdm2 binding proteins and uses thereof - Google Patents

Mammalian mdm2 binding proteins and uses thereof Download PDF

Info

Publication number
US20050277764A1
US20050277764A1 US10/312,954 US31295403A US2005277764A1 US 20050277764 A1 US20050277764 A1 US 20050277764A1 US 31295403 A US31295403 A US 31295403A US 2005277764 A1 US2005277764 A1 US 2005277764A1
Authority
US
United States
Prior art keywords
mdm2
mtbp
cells
binding protein
mammalian
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US10/312,954
Other versions
US7166712B2 (en
Inventor
Mark Boyd
Dale Haines
Nikolina Vlatkovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Philadelphia Health and Education Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/312,954 priority Critical patent/US7166712B2/en
Priority claimed from PCT/US2001/022053 external-priority patent/WO2002004601A2/en
Assigned to PHILADELPHIA, HEALTH AND EDUCATION CORPORATION reassignment PHILADELPHIA, HEALTH AND EDUCATION CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BOYD, MARK THOMAS, HAINES, DALE STEWART, VLATKOVIC, NIKOLINA
Publication of US20050277764A1 publication Critical patent/US20050277764A1/en
Priority to US11/650,159 priority patent/US7304142B2/en
Application granted granted Critical
Publication of US7166712B2 publication Critical patent/US7166712B2/en
Priority to US11/876,901 priority patent/US7732577B2/en
Priority to US12/759,906 priority patent/US20100286362A1/en
Adjusted expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Definitions

  • the present invention relates to the identification of mammalian genes, in particular a mouse and human gene, which encode a protein, referred to herein as MDM2 binding protein or MTBP, which is involved in the MDM2 growth regulatory pathway in cells.
  • MDM2 binding protein or MTBP a protein that is involved in the MDM2 growth regulatory pathway in cells.
  • overexpression of MTBP can induce an arrest in the G 1 phase of the cell cycle.
  • overexpression of MDM2 can block the arresting effects of MTBP in the G 1 phase of the cell cycle and that MDM2 can induce increased turnover of MTBP.
  • MTBP may have tumor suppressive activity.
  • isolated nucleic acid sequences encoding MTBP isolated polypeptide sequences for mammalian MTBP, vectors and host cells for expression of this cellular growth regulating protein and antibodies which target this cellular growth regulating protein.
  • methods and compositions for modulating the G 1 phase of the cell cycle via altering expression levels and/or activity of MTBP are also provided in the present invention.
  • p53 function may be compromised directly, via genetic mutation and/or deletion of the p53 gene (Baker et al. Science 1989 244:217-221) and indirectly by changes in the regulation or level of the MDM2 protein (Oliner et al. Nature 1992 358:80-83).
  • MDM2 The MDM2 gene, itself a transcriptional target of p53 (Barak et al. EMBO J 1993 12:461-468; Juven et al. Oncogene 1993 8:3411-3416; and Wu et al. Genes Dev. 1993 7:1126-1132), encodes a protein, MDM2, that is a critical negative regulator of p53 function (Finlay, C. A. Mol. Cell. Biol. 1993 13:301-306; Momand et al. Cell 1992 69:1237-1245). MDM2 was originally discovered as an oncogene that was amplified on mouse double minute chromosomes (Cahilly-Snyder et al. Cell Mol. Genet. 1987 13:235-244).
  • MDM2 was later found to-be amplified and overexpressed in a variety of human cancers (Ladanyi et al. Cancer Res. 1993 1:16-18; Reifenberger et al. Cancer Res. 1993 53:2736-2739). MDM2 binds to the transcriptional activation domain of p53 and thus inhibits this function of p53 (Chen et al. Mol. Cell Biol. 1993 13:4107-4114; Oliner et al. Nature 1993 362:857-860). Moreover, MDM2 binding to p53 regulates the stability of the p53 protein such that p53 is ubiquitinated and is then degraded by the proteasome (Haupt et al. EMBO J.
  • MDM2 inhibits-both p53 mediated G 1 arrest and apoptosis (Chen et al. Mol. Cell. Biol. 1996 16:2445-2452; Haupt et al. EMBO J 1996 15:1596-1606).
  • p53 induces G 1 arrest by promoting transcriptional upregulation of the CDK inhibitor p2l waf1/cip1 (Waldmann et al. Cancer Res. 1995 55:5187-5190). Therefore, it is likely that MDM2 prevents p53 from inducing G 1 arrest by inhibiting p53 dependent transcriptional activation.
  • MDM2 can prevent p53-mediated apoptosis, and this has been shown to be dependent upon the ability of MDM2 to inhibit transcriptional repression by p53 (Hsieh et al. Mol. Cell 1999 3:81-93). Moreover, a previously identified interaction with RB (Xiao et al. Nature 1995 375:694-698) was shown to be able to regulate this effect. By binding to MDM2, RB forms a stable ternary complex with p53 and this prevents the MDM2 promoted degradation of p53. The ternary complex can promote p53 dependent apoptosis but not p53 mediated transactivation.
  • mice that possess a homozygous deletion of MDM2 die at around day 5 of embryogenesis whereas, mice that possess homozygous deletion of both MDM2 and p53 are viable and develop normally (Jones et al. Nature 1995 378:206-208; Montes de Oca Luna et al. Nature 1995 378:203-206). No differences have been detected between these p53 ⁇ / ⁇ and p53 ⁇ / ⁇ , MDM2 ⁇ / ⁇ mice in terms of the rate or spectrum of tumors developed (Jones et al. Proc. Natl Acad. Sci. USA 1996 93:14106-14111). Also, no differences could be detected between the embryonic fibroblasts derived from these animals in terms of their growth or cell cycle characteristics.
  • MDM2 may be to regulate p53 activity and perhaps, during normal development, this is indeed the case. However, the situation appears to be different when MDM2 is expressed at abnormally high levels.
  • MDM2 was overexpressed in NIH3T3 cells have shown that naturally occurring splice variants of MDM2 that lack the ability to bind to p53 are still able to transform these cells (Sigala et al. Nat. Med. 1996 2:912-917). Further support for the suggestion that MDM2 has p53 independent effects is derived from studies of transgenic mice.
  • mice transgenic for an MDM2 gene expressed from a ⁇ -lactoglobulin promoter exhibited abnormal mammary development, with cells becoming polyploid together with a 15 multinucleate morphology, suggestive of DNA synthesis in the absence of mitosis (Lundgren et al. Genes Dev. 1997 11:714-725). The same results were obtained in both p53 wild type animals and in animals with homozygous deletion of p53.
  • recent studies using a different transgenic system with multiple copies of the whole MDM2 gene being used to generate mice that overexpress MDM2 from the MDM2 promoter have shown that these animals develop a different spectrum of tumors c.f. p53 null mice (Jones et al.
  • MTBP for MDM2 (Two) Binding Protein
  • An object of the present invention is to provide isolated nucleic acid sequences encoding a mammalian MDM2 binding protein.
  • Another object of the present invention is to provide vectors and host cells expressing vectors which comprise nucleic acid sequences encoding a mammalian MDM2 binding protein.
  • Another object of the present invention is to provide isolated polypeptide sequences of a mammalian MDM2 binding protein.
  • Another object of the present invention is to provide antibodies which target a mammalian MDM2 binding protein or a fragment thereof.
  • Yet another object of the present invention is to provide methods and compositions for modulating the G 1 phase of the cell cycle via altering expression of a mammalian MDM2 binding protein or levels and/or activity of a mammalian MDM2 binding protein.
  • compositions capable of modulating expression of a mammalian MDM2 binding protein or levels or activity of this protein include, but are not limited to, antisense agents targeted to a gene encoding a mammalian MDM2 binding protein, ribozymes targeted to a gene encoding a mammalian MDM2 binding protein, peptide mimics of a mammalian MDM2 binding protein, antibodies targeted to a mammalian MDM2 binding protein and modulators of MDM2 expression.
  • MDM2 protein through its interaction with p53 plays an important role in the regulation of the G 1 checkpoint of the cell cycle.
  • MDM2 binds, inter alia, to RB, and the E2F-1/DP-1 complex and in so doing is believed to promote progression of cells into S-phase.
  • Mice transgenic for MDM2 possess cells that have cell cycle regulation detects and develop an altered tumor profile independent of their p53 status.
  • MDM2 also blocks the growth inhibitory effects of TGF-PI in a p53 independent manner.
  • the present invention relates to a novel growth regulatory molecule which is also the target of MDM2 mediated inhibition.
  • MDM2 binding protein MTBP
  • MDM2 binding protein MTBP
  • G 1 arrest As also demonstrated herein, MTBP induction can in turn be blocked by MDM2.
  • MTBP when expressed at high levels can induce growth arrest in vitro. It is therefore believed that the MTBP protein of the present invention may also be a tumor suppressor protein.
  • the MTBP gene and protein of the present invention was first identified in experiments wherein a full length cDNA for murine MDM2 was subcloned into a GAL4 DNA binding domain (GAL4-DBD) yeast expression construct and used to screen a murine T cell lymphoma cDNA library.
  • GAL4-DBD GAL4 DNA binding domain
  • a carboxy terminal cDNA from a novel gene fused to the activation domain of GAL4 (GAL-4-AD-3′MTBP) was found to interact with GAL4-DBD-MDM2 but not with GAL4-DBD. This interaction was confirmed in a different system wherein the in vitro translated cDNA from the yeast two hybrid screen (pBBV-3′ MTBP) was mixed with recombinant His 6 -tagged MDM2.
  • pBBV-3′ MTBP encodes a peptide that can bind in vitro to MDM2. Sequence analysis of this cDNA demonstrated that it is a novel sequence that encodes a predicted peptide of 380 amino acids. Northern analysis demonstrated that the carboxy terminal cDNA hybridized to a mRNA of approximately 3 kb. The rest of the cDNA for this gene was cloned using a RACE-based strategy. Analysis of 5′ RACE products from mRNA obtained from a murine B cell line showed several clones possessing an authentic 5′ end; the clones were identical and terminated upstream of a single long open reading frame that was in frame with the clone identified in the yeast two hybrid screen.
  • This murine clone has been deposited in the Genbank data base (AJ278508) and is depicted herein as SEQ ID NO:1.
  • This cDNA encodes a protein (depicted in SEQ ID NO:4) with a predicted Mw of 104 kD, and this gene is referred to herein as MDM2 (Two) binding protein or MTBP.
  • MDM2 (Two) binding protein or MTBP MDM2 (Two) binding protein or MTBP.
  • a cDNA for human MTBP has also been isolated and sequenced.
  • the sequence of this cDNA and the polypeptide encoded thereby are depicted in SEQ ID NO:3 and 2, respectively.
  • Boi1p and Boi2p exhibit an overall amino acid identity of 38% which is concentrated into four regions (I-IV) that possess identities of 71%, 65%, 78% and 69%, respectively.
  • Both Boi1p and Boi2p inhibit growth in yeast when expressed at high levels. More specifically, these yeast proteins are part of a pathway that is required for maintenance of cell polarity which is necessary for bud formation.
  • Cdc42p a member of the rho family of GTPases together with an associated GTP-GDP exchange factor Cdc24p (reviewed in Cabib et al. Annu. Rev. Biochem. 1998 67:307-333).
  • Boi1p The homology between Boi1p, Boi2p and MTBP is 21.2% and 21% amino acid identity in alignments of 401 and 400 amino acids, respectively, and is entirely contained within the carboxy terminal regions of all three proteins.
  • the growth inhibitory function of Boi2p is entirely contained within the carboxy terminal moiety of the protein.
  • MTBP may also play a role in the regulation of a Cdc42p dependent pathway.
  • Domain three of Boi2p is a proline rich region that is essential for binding to the second src homology region 3 (SH3-2) of Bem1p.
  • the corresponding region of MTBP is also proline rich. Given that many SH3 binding proteins use a region that is rich in proline residues for binding (Grossman et al. Mol. Cell 1998 2:405-415), it is believed that the homologous region of MTBP may also bind to SH3 domains.
  • MTBP The full length cDNA for murine MTBP was used to examine the pattern of expression of this gene by northern blot.
  • MTBP is expressed in a variety of normal tissues with the highest levels of expression being in the thymus, testis and ovary and low or almost undetectable expression in peripheral blood lymphocytes. Thymus, testis and ovary are sites of high levels of cell proliferation and differentiation and moreover are the same tissues that exhibit the highest levels of expression of MDM2 (Fakharzadeh et al. EMBO J 1991 10:1565-1569).
  • MTBP was also detected in pancreas, heart, liver, skeletal muscle, liver and relatively low expression was detected in brain.
  • the cDNA corresponding to amino acids 515 to 894 of MTBP was initially identified via its interaction with MDM2.
  • MDM2 The cDNA corresponding to amino acids 515 to 894 of MTBP was initially identified via its interaction with MDM2.
  • an in vitro binding assay was performed using recombinant His 6 -MDM2 and in vitro translated MTBP. Both this fragment and the full length protein bound to MDM2 in an in vitro assay. This indicates that the interaction of MTBP with MDM2 is likely to be direct. Further confirmation of the interaction between these two proteins came from analysis of mammalian cells transfected with MDM2 and a carboxy-terminal hemagglutinin (HA) tagged form of MTBP.
  • HA hemagglutinin
  • the MDM2 protein has a number of highly conserved regions and the function of these is not fully understood (reviewed in Freedman et al. Cell Mol. Life Sci. 1999 55:96-107).
  • the region of MDM2 that binds to MTBP was determined using a series of carboxy terminal deletion mutants of GAL4-DBD-MDM2.
  • the ability of the mutants to interact in yeast with GAL4-AD-MTBP was assessed. An interaction was detected with all mutants containing the amino terminal 304 amino acids of MDM2 bit not with shorter mutants.
  • a p53 containing construct, GAL4-AD-p53 was also demonstrated to interact with these mutants as well as mutants 1-199 and 1-166, thus indicating that the failure of MTBP to bind to these mutants of MDM2 does not merely reflect lower expression or other conformational problems.
  • the ability of in vitro translated full length MTBP and carboxy terminal MTBP (pBBV-3′MTBP) to bind to both full length MDM2 and to a mutant that lacks the first 166 amino acids ( ⁇ 166) was also examined. ⁇ 166 does not bind to p53. However, it does bind to both full length MTBP and to pBBV-3′MTBP.
  • MDM2 a region of MDM2 bounded by amino acids 167 to 304 is sufficient to bind to MTBP.
  • This region of MDM2 contains a nuclear localization signal, a region identified as a nuclear export signal and an acidic region.
  • results in both yeast and in vitro suggest that the carboxy terminal region of MTBP (amino acid 515-894) is sufficient for binding to MDM2.
  • MDM2 binds to the carboxy terminal 380 amino acids of MTBP and that the region of MDM2 for amino acid 167 to 304 is sufficient for the binding interaction to occur.
  • MDM2 This region of MDM2 overlaps with the MDM2 binding sites for p300, TFIIE, RB and p19 arf (Hsieh et al. Mol. Cell 1999 3:91-93; Xiao et al. Nature 1995 375:694-698; Grossman et al. Mol. Cell 1998 2:405-415; Pomerantz et al. Cell 1998 92:713-723; Zhang et al. Cell 1998 92:725-734; and Thut et al. Genes Dev. 1997 11:1974-1986).
  • the p300 binding region of MDM2 lies between amino acids 102 and 222.
  • telomere binding to MDM2 has been shown to be necessary for MDM2 medicated degradation of p53.
  • the region responsible for interaction of MDM2 with the 34 kD subunit of TFIIE lies between MDM2 amino acids 50-222. This interaction has been implicated in the ability of MDM2 to function as a transcriptional repressor.
  • MTBP acts as a general suppressor of expression, for example by “squelching” or competing for the availability of other transcription factors.
  • H1299 cells were transfected with ⁇ -galactosidase expression construct and the levels of ⁇ -galactosidase were measured by western blot, in the presence of either the MTBP or p53 expression constructs and also with the pCEP vector.
  • MTBP had no effect, whereas p53 reduces the level of ⁇ -galactosidase expression.
  • FACs FACs and no reduction in the number of positive cells or signal strength of CD20 when co-transfected with MTBP was observed. In contrast, a 10% reduction was seen in both with p53.
  • MDM2 blocks p53 mediated cell cycle arrest (Chen et al. Mol. Cell. Biol. 1996 16:2445-2452). Accordingly, its ability to inhibit the effect of MTBP was also examined. Little effect upon the level of MTBP protein was observed. However, it was found that MDM2 expression resulted in complete abrogation of the effect of MTBP in U20S cells. Thus, it is believed that MDM2 mediated inhibition of the MTBP induced cell cycle arrest does not require degradation of MTBP. Further, it is believed that MDM2 suppresses the G 1 arrest mediated by MTBP and since this does not require degradation of MTBP, it seems likely that the effect is a consequence of the ability of MDM2 to bind directly to MTBP.
  • the present invention also relates to vectors expressing this new protein as well as host cells comprising such vector which express these new proteins.
  • vectors and host cells known in the art can be used and selection of appropriate vectors and host cells for expression of MTBP can be performed routinely by those of skill in the art.
  • Mammalian MTBP polypeptides prepared via these vectors and host cells or synthetically are useful in raising antibodies targeted to the mammalian MTBP polypeptides.
  • Methods for raising both polyclonal and monoclonal antibodies are well known to those of skill in the art.
  • raising antibodies specific for the mammalian MTBP polypeptides of the present invention can be performed routinely by those skilled in the art.
  • Such antibodies are not only useful in further elucidation of the function of this protein, but also in methods for detecting these polypeptides and in methods for identifying modulators of the expression and/or activity of this proteins.
  • compositions capable of modulating expression of MTBP or levels or activity of MTBP include, but are not limited to antisense agents targeted to MTBP, ribozymes targeted to MTBP, peptide mimics of MTBP and modulators of MDM2 expression. Identification and development, as well as testing or screening, of such compositions can be performed routinely by those of skill in the art based upon the teachings provided herein relating to these new MTBP genes and proteins and their activity. Compositions which modulate MTBP levels or activity may be useful in suppressing tumors.
  • pGAL4-DBD-MDM2 encodes full length mouse MDM2 cloned in-frame with the GAL4 DNA binding domain (DBD) of pGBT9 (Clontech).
  • pGAL4-AD-MTBP-3′ contains the carboxy terminal 380 amino acids of MTBP cloned into the XhoI site of pACT (Clontech).
  • pBBV was generated by inserting an oligonucleotide containing the black beetle virus ribosome binding sequences from pBD7 (Dasmahapatra et al. Nucleic Acids Res. 1987 15:3933) into the HindIII and EcoRV sites of pcDNAI Neo (Invitrogen).
  • pSK-BBV was generated by subcloning a HindIII/BglII DNA fragment containing the black beetle virus ribosome binding sequence from pBBV into the HindIII and BamHI sites of plasmid pBluescript SKII+ (Stratagene).
  • Clones identified as encoding candidate MDM2 interacting molecules in the yeast two hybrid screen analysis were amplified from pACT with GAD5 (5′ gag aga gat atc gcc aat ttt aat caa agt ggg aat att 3′ (SEQ ID NO:11)) and GAD3 (5′ gag aga gcg gcc gct ttc agt atc tac gat tca tag atc tc 3′ (SEQ ID NO:12)) primers and subcloned into the EcoRV and NotI sites of pBBV.
  • GAD5 5′ gag aga gat atc gcc aat ttt aat caa agt ggg aat att 3′
  • GAD3 5′ gag aga gcg gcc gct ttc agt atc tac gat tca tag atc tc 3′ (SEQ ID NO:
  • pBBV-MTBP-3′ was constructed by subcloning this PCR generated fragment from pGAL4-AD-MTBP-3′ into pBBV.
  • the pSK-MTBP construct used for in vitro translation of full length MTBP was made by sub-cloning the NotI fragment from pCEP-MTBP into the NotI site of pSK-BBV.
  • Recombinant His 6 -tagged MDM2 (pQE32-MDM2) was generated by cloning an EcoRV/XhoI fragment from pBBV-MDM2 encoding the full length murine MDM2 cDNA into the SmaI site of pQE32 (Qiagen).
  • Recombinant His 6 -tagged ⁇ 166 contains a DNA fragment of murine MDM2 lacking the first 166 amino acid residues.
  • the fragment was amplified from pCMVNeoBam-Mdm2 by PCR with primers MDM2 PstI (5′ gag aga ctg cag gag aac aca gat gag cta cct gg 3′ (SEQ ID NO:5)) and MDM2 HindIII (5′gag aga aag ct gtc agc tag ttg aag taa ctt agc a 3′ (SEQ ID NO:6)) using rTth-XL polymerase (Perkin-Elmer) and cloned into the PstI and HindIII sites of pQE31 (Qiagen).
  • MTBP contains full length murine cDNA for MTBP excised from the pCR-XL-TOPO vector and cloned into the NotI site of pCEP (Invitrogen).
  • p53 contains full length human p53 cloned into the pCEP vector.
  • the p53 antibody Ab-1 (PAb421), the MDM2 antibody used for western blotting Ab-1 (IF2) and the anti- ⁇ -galactosidase antibody Ab-1 (200-193) were purchased from Oncogene Research Products.
  • the MDM2 antibody used for immunoprecipitation, SMP14, and the antibody used to detect p21 waf1/cip1 (F-5) were purchased from Santa Cruz Biotechnology, Inc.
  • HA antibodies (12CA5 and 16BI2) used to detect HA-tagged MTBP were purchased from Roche Molecular Biologicals and BAbCO, respectively.
  • the anti-CD20 antibody leu16 was purchased from Becton Dickinson-and the anti-mouse-IgG-FITC conjugate was obtained from Pierce.
  • the MATCHMAKER system (Clontech) was used to screen a mouse T-cell lymphoma library (ML4001AE) and to assess interactions between the GAL4-DBD-MTBP and GAL4-AD-MDM2 deletion mutants.
  • the Marathon RACE system (Clontech) was used to amplify the 5′ and 3′ ends of MTBP from a murine B cell cDNA.
  • Total cellular RNA was prepared from murine SP2 (ATCC# CRL-1646) cells using RNAZOL (MBI) and poly A+ RNA was isolated from this using OLIGOTEX beads (Qiagen).
  • 5-prime RACE was performed using the gene specific oligonucleotides GSP-1 (5′tga aga ata agg ttc aac tgt acc 3′ (SEQ ID NO:7)) and GSP-2 (5′cag ctt tca cgg tgt ctg ttt g 3′ (SEQ ID NO:8)). PCR was performed with rTth-XL and products were cloned into pCR2.1 (Invitrogen). 3-prime RACE was also performed and confirmed the termination codon identified in the yeast two hybrid screen. Sequencing was performed using dye terminators and an ABI-373 sequencer.
  • cDNA for MTBP was prepared by PCR amplification with the oligonucleotides MTBP-5′-NotI (5′ gag aga gcg gcc gcg gcg cga aga gga tgg atc ggt act tgc tg 3′ (SEQ ID NO:9)) and MTBP-3′-HA-NotI (5′gag aga gcg gcc gcc tac agg gag gcg taa tcg ggc aca tcg tag ggg tat ttc ttg ctc atc ttttct acc acc 3′ (SEQ ID NO:10)) using rTth-XL and the product was cloned into PCR-XL-TOPO (In
  • MDM2 or ⁇ 166-MDM2 were expressed in XL-1 bacteria (Stratagene) from the pQE32-MDM2 and pQE31- ⁇ 166-MDM2 constructs, respectively, captured on Ni ++ -agarose (Qiagen) and washed with buffers B, C and D as described by the manufacturer. Prior to all binding reactions, protein captured onto beads was run on a SDS-polyacrylamide gel and analyzed by both western blotting and staining with coomassie blue.
  • Washed beads (100 ⁇ l) were then mixed with 10 ⁇ l of in vitro translated protein (TNT, Promega) for 3 hours at 30° C., followed by washing three times in Dignam's buffer D supplemented with 75 mM imidazole (Dignam et al. Nucleic Acids Res. 1983 11:1475-1489). Beads were then resuspended in loading buffer and analyzed by SDS-PAGE and fluorography using AMPLIFY (Amersham Pharmacia).
  • TNT in vitro translated protein
  • Transfected cells were harvested and the cell pellet lysed in IP buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, 0.10-0 TRITON-X100, 0.5 mg/ml BSA) in the presence of the protease inhibitors: 1-2 ⁇ g/ml aprotinin, 1-2 ⁇ g/ml leupeptin, 1 ⁇ g/ml pepstatin A, 100 ⁇ g/ml soybean trypsin inhibitor (Roche) and 1 mM phenylmethylsulfonylfluoride, for 10 minutes, on ice. The lysate was clarified by centrifugation for 10 minutes at 4° C.
  • IP buffer 50 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, 0.10-0 TRITON-X100, 0.5 mg/ml BSA
  • protease inhibitors 1-2 ⁇ g/ml aprotinin,
  • Bio-Rad Protein Assay BioRad. Between 1 and 5 mg of protein was then pre-cleared by incubation with 50 ⁇ l of protein G-sepharose (Amersham Pharmacia) for 1 hour at 4° C. Pre-cleared lysate was incubated with 1 ⁇ g of primary antibody for 1 hour at 4° C., followed by incubation with 50 ⁇ l of protein G-sepharose for 2 hours at 4° C.
  • Immunoprecipitated complexes were washed three times with IP buffer, resuspended in 30 ⁇ l of protein sample buffer (0.1 M Tris-HCl, pH 6-8, 4% SDS, 0.2% bromophenol blue, 20% glycerol, 0.5 M DTT) and subjected to SDS-PAGE followed by transfer to Hybond-ECL membrane (Amersham Pharmacia). Following incubation with primary antibodies and subsequently with anti-mouse-IgG-HRP (Amersham Pharmacia), the signal was detected by enhanced chemiluminescence with RENAISSANCE (NEN).
  • protein sample buffer 0.1 M Tris-HCl, pH 6-8, 4% SDS, 0.2% bromophenol blue, 20% glycerol, 0.5 M DTT
  • H1299 cells were transtected using either the calcium phosphate precipitation method or FUGENE-6. Typically for the calcium phosphate precipitate procedure, 24 hours after removal of precipitates, hygromycin B (Roche) was added to a final concentration of 200 ⁇ g/ml. Cells were maintained under selective conditions for 72 hours, washed and refed with hygromycin-free complete media. Nocodazole (Sigma) was added as indicated at a concentration of 20 ng/ml, 16 hours before cells were harvested for analysis.
  • hygromycin-B was added at a final concentration of 200 ⁇ g/ml. Cells were refed every three days with media containing Hygromycin-B until colonies were visible. For some experiments cells were stained with Giemsa.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Isolated nucleic acid sequences encoding mammalian MDM2 binding protein and polypeptide sequences for the mammalian MDM2 binding protein are provided. Also provided are vectors containing these nucleic acid sequences, host cells which express these proteins and antibodies targeted to these proteins. In addition, methods and compositions for modulating the G1 phase of the cell cycle via altering expression and/or activity of a mammalian MDM2 binding protein are provided.

Description

    INTRODUCTION
  • This invention was supported in part by funds from the U.S. government (NIH Grant No. CA70165) and the U.S. government may therefore have certain rights in the invention.
    • FIELD OF THE INVENTION
  • The present invention relates to the identification of mammalian genes, in particular a mouse and human gene, which encode a protein, referred to herein as MDM2 binding protein or MTBP, which is involved in the MDM2 growth regulatory pathway in cells. Specifically, it has been found that overexpression of MTBP can induce an arrest in the G1 phase of the cell cycle. Further, it has been found that overexpression of MDM2 can block the arresting effects of MTBP in the G1 phase of the cell cycle and that MDM2 can induce increased turnover of MTBP. Thus, it is believed that MTBP may have tumor suppressive activity. Accordingly, provided in the present invention are isolated nucleic acid sequences encoding MTBP, isolated polypeptide sequences for mammalian MTBP, vectors and host cells for expression of this cellular growth regulating protein and antibodies which target this cellular growth regulating protein. Also provided in the present invention are methods and compositions for modulating the G1 phase of the cell cycle via altering expression levels and/or activity of MTBP.
    • BACKGROUND OF THE INVENTION
  • In tumors, loss of function of either p53 itself (Hollstein et al. Nucleic Acids Res. 1996 24:141-146; Nigro et al. Nature 1989 342:705-708), or of the p53 dependent pathway that activates G1 arrest, is one of the major and most frequent molecular events (reviewed in Sherr, C. J. Genes Dev. 1998 12:2984-2991). p53 function may be compromised directly, via genetic mutation and/or deletion of the p53 gene (Baker et al. Science 1989 244:217-221) and indirectly by changes in the regulation or level of the MDM2 protein (Oliner et al. Nature 1992 358:80-83). The MDM2 gene, itself a transcriptional target of p53 (Barak et al. EMBO J 1993 12:461-468; Juven et al. Oncogene 1993 8:3411-3416; and Wu et al. Genes Dev. 1993 7:1126-1132), encodes a protein, MDM2, that is a critical negative regulator of p53 function (Finlay, C. A. Mol. Cell. Biol. 1993 13:301-306; Momand et al. Cell 1992 69:1237-1245). MDM2 was originally discovered as an oncogene that was amplified on mouse double minute chromosomes (Cahilly-Snyder et al. Cell Mol. Genet. 1987 13:235-244). MDM2 was later found to-be amplified and overexpressed in a variety of human cancers (Ladanyi et al. Cancer Res. 1993 1:16-18; Reifenberger et al. Cancer Res. 1993 53:2736-2739). MDM2 binds to the transcriptional activation domain of p53 and thus inhibits this function of p53 (Chen et al. Mol. Cell Biol. 1993 13:4107-4114; Oliner et al. Nature 1993 362:857-860). Moreover, MDM2 binding to p53 regulates the stability of the p53 protein such that p53 is ubiquitinated and is then degraded by the proteasome (Haupt et al. EMBO J. 1996 15:1596-1606; Kubbutat et al. Nature 1997 387:299-303). This, together with the observed effect upon p53 function, has led to a model in which an autoregulatory loop connects MDM2 and p53 (Barak et al. EMBO J 1993 12:461-468; Wu et al. Genes Dev. 1993 7:1126-1132).
  • MDM2 inhibits-both p53 mediated G1 arrest and apoptosis (Chen et al. Mol. Cell. Biol. 1996 16:2445-2452; Haupt et al. EMBO J 1996 15:1596-1606). p53 induces G1 arrest by promoting transcriptional upregulation of the CDK inhibitor p2lwaf1/cip1 (Waldmann et al. Cancer Res. 1995 55:5187-5190). Therefore, it is likely that MDM2 prevents p53 from inducing G1 arrest by inhibiting p53 dependent transcriptional activation. MDM2 can prevent p53-mediated apoptosis, and this has been shown to be dependent upon the ability of MDM2 to inhibit transcriptional repression by p53 (Hsieh et al. Mol. Cell 1999 3:81-93). Moreover, a previously identified interaction with RB (Xiao et al. Nature 1995 375:694-698) was shown to be able to regulate this effect. By binding to MDM2, RB forms a stable ternary complex with p53 and this prevents the MDM2 promoted degradation of p53. The ternary complex can promote p53 dependent apoptosis but not p53 mediated transactivation.
  • The autoregulatory relationship between p53 and MDM2 suggests that MDM2 overexpression may be oncogenic because of the resulting inactivation of p53 (Wu et al. Genes Dev. 1993 7:1126-1132). This conclusion is supported by studies of human tumors which show that in the majority of cases either p53 is mutated/deleted or MDM2 is overexpressed (Leach et al. Cancer Res. 1993 53:2231-2234). Studies of allelic knockouts of these genes in mice further support the ability to negatively regulate p53 being a primary function of MDM2. Mice that possess a homozygous deletion of MDM2 die at around day 5 of embryogenesis whereas, mice that possess homozygous deletion of both MDM2 and p53 are viable and develop normally (Jones et al. Nature 1995 378:206-208; Montes de Oca Luna et al. Nature 1995 378:203-206). No differences have been detected between these p53 −/− and p53 −/−, MDM2 −/− mice in terms of the rate or spectrum of tumors developed (Jones et al. Proc. Natl Acad. Sci. USA 1996 93:14106-14111). Also, no differences could be detected between the embryonic fibroblasts derived from these animals in terms of their growth or cell cycle characteristics.
  • Collectively, these observations suggest that the primary function of MDM2 may be to regulate p53 activity and perhaps, during normal development, this is indeed the case. However, the situation appears to be different when MDM2 is expressed at abnormally high levels. Experiments in which MDM2 was overexpressed in NIH3T3 cells have shown that naturally occurring splice variants of MDM2 that lack the ability to bind to p53 are still able to transform these cells (Sigala et al. Nat. Med. 1996 2:912-917). Further support for the suggestion that MDM2 has p53 independent effects is derived from studies of transgenic mice. Mice transgenic for an MDM2 gene expressed from a β-lactoglobulin promoter, exhibited abnormal mammary development, with cells becoming polyploid together with a 15 multinucleate morphology, suggestive of DNA synthesis in the absence of mitosis (Lundgren et al. Genes Dev. 1997 11:714-725). The same results were obtained in both p53 wild type animals and in animals with homozygous deletion of p53. In addition, recent studies using a different transgenic system with multiple copies of the whole MDM2 gene being used to generate mice that overexpress MDM2 from the MDM2 promoter, have shown that these animals develop a different spectrum of tumors c.f. p53 null mice (Jones et al. Proc. Natl Acad. Sci. USA 1998 95:15608-15612). The same effect of MDM2 overexpression was observed regardless of the p53 status of these animals. Finally, in support of the existence of p53 independent effects of MDM2 upon overexpression, it has recently been shown that MDM2 has the ability to abrogate the growth inhibitory activities of Transforming Growth Factor-Beta1 (TGFβ1). This effect was p53 independent in cells in culture (Sun et al. Science 1998 282:2270-2272). Taken together, these results all suggest that overexpression of MDM2 acts not only upon p53 but also on additional pathways.
  • Using a yeast two hybrid screen a novel gene encoding a protein referred to herein as MTBP for MDM2 (Two) Binding Protein has now been identified. MTBP is demonstrated herein-to be capable of negatively regulating growth by inducing G1 arrest in a p53 independent manner. Further, this negative regulation of growth can be suppressed by MDM2.
    • SUMMARY OF THE INVENTION
  • An object of the present invention is to provide isolated nucleic acid sequences encoding a mammalian MDM2 binding protein.
  • Another object of the present invention is to provide vectors and host cells expressing vectors which comprise nucleic acid sequences encoding a mammalian MDM2 binding protein.
  • Another object of the present invention is to provide isolated polypeptide sequences of a mammalian MDM2 binding protein.
  • Another object of the present invention is to provide antibodies which target a mammalian MDM2 binding protein or a fragment thereof.
  • Yet another object of the present invention is to provide methods and compositions for modulating the G1 phase of the cell cycle via altering expression of a mammalian MDM2 binding protein or levels and/or activity of a mammalian MDM2 binding protein. Examples of compositions capable of modulating expression of a mammalian MDM2 binding protein or levels or activity of this protein include, but are not limited to, antisense agents targeted to a gene encoding a mammalian MDM2 binding protein, ribozymes targeted to a gene encoding a mammalian MDM2 binding protein, peptide mimics of a mammalian MDM2 binding protein, antibodies targeted to a mammalian MDM2 binding protein and modulators of MDM2 expression.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The MDM2 protein, through its interaction with p53 plays an important role in the regulation of the G1 checkpoint of the cell cycle. In addition to binding to and inhibiting the transcriptional activation function of the p53 protein, MDM2 binds, inter alia, to RB, and the E2F-1/DP-1 complex and in so doing is believed to promote progression of cells into S-phase. Mice transgenic for MDM2 possess cells that have cell cycle regulation detects and develop an altered tumor profile independent of their p53 status. MDM2 also blocks the growth inhibitory effects of TGF-PI in a p53 independent manner.
  • The present invention relates to a novel growth regulatory molecule which is also the target of MDM2 mediated inhibition. Using a yeast two-hybrid screen, a gene that encodes a cellular protein, referred to herein as MDM2 binding protein (MTBP), that binds to MDM2 has now been identified. As demonstrated herein, MTBP induces G1 arrest. As also demonstrated herein, MTBP induction can in turn be blocked by MDM2. These results indicate MTBP to be involved in a p53-independent growth control pathway regulated, at least in part, by MDM2. It is believed that the protein of the present invention, MTBP provides an additional link between MDM2 function and regulation of the G1 cell cycle checkpoint. Thus, like a number of tumor suppressor proteins such as p53, E2F-1, RB and p19Arf which interact with MDM2, MTBP when expressed at high levels can induce growth arrest in vitro. It is therefore believed that the MTBP protein of the present invention may also be a tumor suppressor protein.
  • The MTBP gene and protein of the present invention was first identified in experiments wherein a full length cDNA for murine MDM2 was subcloned into a GAL4 DNA binding domain (GAL4-DBD) yeast expression construct and used to screen a murine T cell lymphoma cDNA library. A carboxy terminal cDNA from a novel gene fused to the activation domain of GAL4 (GAL-4-AD-3′MTBP) was found to interact with GAL4-DBD-MDM2 but not with GAL4-DBD. This interaction was confirmed in a different system wherein the in vitro translated cDNA from the yeast two hybrid screen (pBBV-3′ MTBP) was mixed with recombinant His6-tagged MDM2. pBBV-3′ MTBP encodes a peptide that can bind in vitro to MDM2. Sequence analysis of this cDNA demonstrated that it is a novel sequence that encodes a predicted peptide of 380 amino acids. Northern analysis demonstrated that the carboxy terminal cDNA hybridized to a mRNA of approximately 3 kb. The rest of the cDNA for this gene was cloned using a RACE-based strategy. Analysis of 5′ RACE products from mRNA obtained from a murine B cell line showed several clones possessing an authentic 5′ end; the clones were identical and terminated upstream of a single long open reading frame that was in frame with the clone identified in the yeast two hybrid screen. The sequence of this murine clone has been deposited in the Genbank data base (AJ278508) and is depicted herein as SEQ ID NO:1. This cDNA encodes a protein (depicted in SEQ ID NO:4) with a predicted Mw of 104 kD, and this gene is referred to herein as MDM2 (Two) binding protein or MTBP. We have also referred to this gene as p104.
  • A cDNA for human MTBP has also been isolated and sequenced. The sequence of this cDNA and the polypeptide encoded thereby are depicted in SEQ ID NO:3 and 2, respectively.
  • Database analysis identified two yeast genes, BOI1 and BOI2, whose protein products possessed significant homology to murine MTBP,(Bender et al. J. Cell Biol. 1996 133:879-894; Matsui et al. J. Cell Biol. 133:865-878). The two proteins encoded by the genes, Boi1p and Boi2p, exhibit an overall amino acid identity of 38% which is concentrated into four regions (I-IV) that possess identities of 71%, 65%, 78% and 69%, respectively. Both Boi1p and Boi2p inhibit growth in yeast when expressed at high levels. More specifically, these yeast proteins are part of a pathway that is required for maintenance of cell polarity which is necessary for bud formation. This pathway is regulated by Cdc42p, a member of the rho family of GTPases together with an associated GTP-GDP exchange factor Cdc24p (reviewed in Cabib et al. Annu. Rev. Biochem. 1998 67:307-333).
  • The homology between Boi1p, Boi2p and MTBP is 21.2% and 21% amino acid identity in alignments of 401 and 400 amino acids, respectively, and is entirely contained within the carboxy terminal regions of all three proteins. Interestingly, the growth inhibitory function of Boi2p is entirely contained within the carboxy terminal moiety of the protein. Thus, it is believed that MTBP may also play a role in the regulation of a Cdc42p dependent pathway.
  • Domain three of Boi2p is a proline rich region that is essential for binding to the second src homology region 3 (SH3-2) of Bem1p. The corresponding region of MTBP is also proline rich. Given that many SH3 binding proteins use a region that is rich in proline residues for binding (Grossman et al. Mol. Cell 1998 2:405-415), it is believed that the homologous region of MTBP may also bind to SH3 domains.
  • Apart from ESTs, no other substantial homologies to MTBP were identified.
  • Numerous sequence motifs were identified within MTBP. In particular, six potential nuclear localization signals were detected (both mono- and bi-partite), which are compatible with a nuclear localization for this protein.
  • The full length cDNA for murine MTBP was used to examine the pattern of expression of this gene by northern blot. MTBP is expressed in a variety of normal tissues with the highest levels of expression being in the thymus, testis and ovary and low or almost undetectable expression in peripheral blood lymphocytes. Thymus, testis and ovary are sites of high levels of cell proliferation and differentiation and moreover are the same tissues that exhibit the highest levels of expression of MDM2 (Fakharzadeh et al. EMBO J 1991 10:1565-1569). MTBP was also detected in pancreas, heart, liver, skeletal muscle, liver and relatively low expression was detected in brain.
  • The cDNA corresponding to amino acids 515 to 894 of MTBP was initially identified via its interaction with MDM2. To test whether the interaction detected between this carboxy terminal region of MTBP and MDM2 also occurred between the full length form of the protein, an in vitro binding assay was performed using recombinant His6-MDM2 and in vitro translated MTBP. Both this fragment and the full length protein bound to MDM2 in an in vitro assay. This indicates that the interaction of MTBP with MDM2 is likely to be direct. Further confirmation of the interaction between these two proteins came from analysis of mammalian cells transfected with MDM2 and a carboxy-terminal hemagglutinin (HA) tagged form of MTBP. Further, immunoprecipitation with either an anti HA MAb or an anti MDM2 MAb followed by western blot analysis, demonstrated that the two proteins could be co-precipitated. These results indicate that the newly identified protein of the present invention, MTBP, binds specifically to MDM2 under these conditions.
  • The MDM2 protein has a number of highly conserved regions and the function of these is not fully understood (reviewed in Freedman et al. Cell Mol. Life Sci. 1999 55:96-107). The region of MDM2 that binds to MTBP was determined using a series of carboxy terminal deletion mutants of GAL4-DBD-MDM2. The ability of the mutants to interact in yeast with GAL4-AD-MTBP was assessed. An interaction was detected with all mutants containing the amino terminal 304 amino acids of MDM2 bit not with shorter mutants. A p53 containing construct, GAL4-AD-p53, was also demonstrated to interact with these mutants as well as mutants 1-199 and 1-166, thus indicating that the failure of MTBP to bind to these mutants of MDM2 does not merely reflect lower expression or other conformational problems. The ability of in vitro translated full length MTBP and carboxy terminal MTBP (pBBV-3′MTBP) to bind to both full length MDM2 and to a mutant that lacks the first 166 amino acids (Δ166) was also examined. Δ166 does not bind to p53. However, it does bind to both full length MTBP and to pBBV-3′MTBP. Thus, taken together, these results indicate that a region of MDM2 bounded by amino acids 167 to 304 is sufficient to bind to MTBP. This region of MDM2 contains a nuclear localization signal, a region identified as a nuclear export signal and an acidic region. Results in both yeast and in vitro suggest that the carboxy terminal region of MTBP (amino acid 515-894) is sufficient for binding to MDM2. Thus it is believed that MDM2 binds to the carboxy terminal 380 amino acids of MTBP and that the region of MDM2 for amino acid 167 to 304 is sufficient for the binding interaction to occur. This region of MDM2 overlaps with the MDM2 binding sites for p300, TFIIE, RB and p19arf (Hsieh et al. Mol. Cell 1999 3:91-93; Xiao et al. Nature 1995 375:694-698; Grossman et al. Mol. Cell 1998 2:405-415; Pomerantz et al. Cell 1998 92:713-723; Zhang et al. Cell 1998 92:725-734; and Thut et al. Genes Dev. 1997 11:1974-1986). For example, the p300 binding region of MDM2 lies between amino acids 102 and 222. p300 binding to MDM2; has been shown to be necessary for MDM2 medicated degradation of p53. The region responsible for interaction of MDM2 with the 34 kD subunit of TFIIE lies between MDM2 amino acids 50-222. This interaction has been implicated in the ability of MDM2 to function as a transcriptional repressor. The region of MDM2 responsible for binding to RB, amino acids 272 to 320, also overlaps with the MTBP binding region. It has recently been shown that by binding to MDM2, RB (preferentially the hypophosphorylated form) can form a ternary complex with p53 that is distinct from the p19Arf/MDM2/p53 complex and appears to perform a distinct function. Experiments to determine whether MTBP can compete with RB or TFIIE for binding to MDM2 are in progress. p19Arf binds to a region of MDM2 that lies between amino acids 154-221 (plus a further interaction point contained with the carboxy terminal 271 amino acids) and in so doing prevents MDM2 from targeting p53 for degradation.
  • Several MDM2 binding proteins are regulators of cell growth. Further, both of the MTBP partial homologues, BOI1 and BOI2, have been shown to have growth inhibitory activity. Therefore the effect of MTBP expression upon cell growth in culture was examined. In these experiments, it was found that, in contrast to the empty vector controls, when an expression construct for MTBP was transfected into U20S cells no colonies were produced. Since U20S cells harbor wild type p53, it was believed that the observed effect of MTBP expression may be dependent upon p53. To examine this, H1299 cells that possess a homozygous deletion of the p53 gene were transfected with MTBP and for comparison, with p53, expressed from the same vector and a vector control. Expression of MTBP was found to reduce colony formation to approximately the same degree as p53. These results indicate that MTBP possesses similar growth inhibitory properties in these p53 null cells compared to U20S cells that contained wild type p53. Similar experiments were performed with Saos-2 cells. Only a slight reduction of approximately three- to four-fold in colony formation was observed in these cells. Since, amongst other alterations, these cells lack both p53 and RB it is believed that the growth inhibitory effect of MTBP may require the presence of RB.
  • A possible explanation for the growth inhibitory effect observed is that MTBP acts as a general suppressor of expression, for example by “squelching” or competing for the availability of other transcription factors. To investigate this H1299 cells were transfected with β-galactosidase expression construct and the levels of β-galactosidase were measured by western blot, in the presence of either the MTBP or p53 expression constructs and also with the pCEP vector. MTBP had no effect, whereas p53 reduces the level of β-galactosidase expression. A similar analysis was performed in a more quantitative fashion using FACs and no reduction in the number of positive cells or signal strength of CD20 when co-transfected with MTBP was observed. In contrast, a 10% reduction was seen in both with p53.
  • An alternative explanation for the growth inhibitory effect observed in U20S cells is the activation of p53. In these cells p53 is wild type but is transcriptionally inactive because of the presence of high levels of MDM2 (Florenes et al. J. Natl Cancer Inst. 1994 86:1297-1302). Thus, transfection of MTBP could simply compete with p53 for binding of MDM2 and in so doing release the MDM2 mediated block. To examine the possibility, levels of p53 itself and of the p53 transcriptional target, p21waf1/cip1 in the presence of MTBP were measured. No alteration in the levels of either of these proteins was seen. Taken together, these observations indicate that high level expression of MTBP has a negative effect upon cell growth and that this is independent of p53.
  • Cell cycle analysis was performed to examine the possibility that MTBP might act at a specific point in the cell cycle. Cells were co-transfected with an expression construct for CD20 so that only the transfected cell population need be analyzed (van den Heuvel, S. And Harlow, E. Science 1993 262:2050-2054). At any given time in a rapidly cycling population of the cells which were used, typically 50% will have a 2N DNA complement. Initial experiments indicated that MTBP expression induces an increase in the percentage of cells with a 2N DNA complement. To examine this further and to facilitate detection of effects in this region of the cell cycle, cells were treated with the microtubule-disrupting drug nocodazole. The result of MTBP expression in U20S cells was compared to cells that were transfected with the vector alone and also with cells transfected with p53 expressed from the same vector. p53 expression induced an increase in the percentage of cells in G1 from 15.9 to 24.9%. MTBP expression induced a similar effect with an increase to 24.0%. As with the growth inhibition that was detected, the possibility existed that the effect observed for MTBP expression upon the cell cycle was in some manner dependent upon p53. To examine this, a similar experiment was performed with H1299 cells. It was found that both p53 and MTBP induce a comparable increase in the percentage of cells with a 2N DNA content from 22.4 to 35.8 and 38.3%, respectively. These experiments were performed on at least three occasions and similar results were obtained each time. These results indicate that p53 is not required for MTBP mediated cell cycle arrest.
  • The effect of MTBP expression upon Saos-2 cells was also examined since these cells appear to be resistant to the growth inhibitory effect of MTBP expression. Analysis of these cells clearly demonstrated that expression of MTBP had no effect upon their cell cycle. These results indicate that the ability of MTBP to inhibit colony formation is consistent with its ability to alter the cell cycle. Thus, from these experiments it is believed that MTBP induces G1 arrest in a p53 independent manner.
  • MDM2 blocks p53 mediated cell cycle arrest (Chen et al. Mol. Cell. Biol. 1996 16:2445-2452). Accordingly, its ability to inhibit the effect of MTBP was also examined. Little effect upon the level of MTBP protein was observed. However, it was found that MDM2 expression resulted in complete abrogation of the effect of MTBP in U20S cells. Thus, it is believed that MDM2 mediated inhibition of the MTBP induced cell cycle arrest does not require degradation of MTBP. Further, it is believed that MDM2 suppresses the G1 arrest mediated by MTBP and since this does not require degradation of MTBP, it seems likely that the effect is a consequence of the ability of MDM2 to bind directly to MTBP.
  • In addition to providing nucleic acid sequences and polypeptides encoded thereby of mammalian MTBP, the present invention also relates to vectors expressing this new protein as well as host cells comprising such vector which express these new proteins. Various vectors and host cells known in the art can be used and selection of appropriate vectors and host cells for expression of MTBP can be performed routinely by those of skill in the art.
  • Mammalian MTBP polypeptides prepared via these vectors and host cells or synthetically are useful in raising antibodies targeted to the mammalian MTBP polypeptides. Methods for raising both polyclonal and monoclonal antibodies are well known to those of skill in the art. Thus, raising antibodies specific for the mammalian MTBP polypeptides of the present invention can be performed routinely by those skilled in the art. Such antibodies are not only useful in further elucidation of the function of this protein, but also in methods for detecting these polypeptides and in methods for identifying modulators of the expression and/or activity of this proteins.
  • The vectors and host cells of the present invention are also useful in the development of methods and compositions for modulating the G1 phase of the cell cycle via altering expression of MTBP or levels and/or activity of MTBP. Examples of compositions capable of modulating expression of MTBP or levels or activity of MTBP include, but are not limited to antisense agents targeted to MTBP, ribozymes targeted to MTBP, peptide mimics of MTBP and modulators of MDM2 expression. Identification and development, as well as testing or screening, of such compositions can be performed routinely by those of skill in the art based upon the teachings provided herein relating to these new MTBP genes and proteins and their activity. Compositions which modulate MTBP levels or activity may be useful in suppressing tumors.
  • The following nonlimiting examples are provided to further illustrate the present invention.
    • EXAMPLES Example 1 Cell Culture, Plasmids and Antibodies
  • Cells were grown in RPMI supplemented with 10% fetal calf serum, and 1% penicillin, streptomycin, and neomycin (Gibco-BRL). H1299 (ATCC# CRL-5803), U20S (ATCC# HTB-96) and Saos-2 (ATCC# HTB-85) cells were obtained from the ATCC. pGAL4-DBD-MDM2 encodes full length mouse MDM2 cloned in-frame with the GAL4 DNA binding domain (DBD) of pGBT9 (Clontech). pGAL4-AD-MTBP-3′ contains the carboxy terminal 380 amino acids of MTBP cloned into the XhoI site of pACT (Clontech). pBBV was generated by inserting an oligonucleotide containing the black beetle virus ribosome binding sequences from pBD7 (Dasmahapatra et al. Nucleic Acids Res. 1987 15:3933) into the HindIII and EcoRV sites of pcDNAI Neo (Invitrogen). pSK-BBV was generated by subcloning a HindIII/BglII DNA fragment containing the black beetle virus ribosome binding sequence from pBBV into the HindIII and BamHI sites of plasmid pBluescript SKII+ (Stratagene). Clones identified as encoding candidate MDM2 interacting molecules in the yeast two hybrid screen analysis were amplified from pACT with GAD5 (5′ gag aga gat atc gcc aat ttt aat caa agt ggg aat att 3′ (SEQ ID NO:11)) and GAD3 (5′ gag aga gcg gcc gct ttc agt atc tac gat tca tag atc tc 3′ (SEQ ID NO:12)) primers and subcloned into the EcoRV and NotI sites of pBBV. pBBV-MTBP-3′ was constructed by subcloning this PCR generated fragment from pGAL4-AD-MTBP-3′ into pBBV. The pSK-MTBP construct used for in vitro translation of full length MTBP was made by sub-cloning the NotI fragment from pCEP-MTBP into the NotI site of pSK-BBV. Recombinant His6-tagged MDM2 (pQE32-MDM2) was generated by cloning an EcoRV/XhoI fragment from pBBV-MDM2 encoding the full length murine MDM2 cDNA into the SmaI site of pQE32 (Qiagen). Recombinant His6-tagged Δ166 (pQE31-Δ166 MDM2) contains a DNA fragment of murine MDM2 lacking the first 166 amino acid residues. The fragment was amplified from pCMVNeoBam-Mdm2 by PCR with primers MDM2 PstI (5′ gag aga ctg cag gag aac aca gat gag cta cct gg 3′ (SEQ ID NO:5)) and MDM2 HindIII (5′gag aga aag ct gtc agc tag ttg aag taa ctt agc a 3′ (SEQ ID NO:6)) using rTth-XL polymerase (Perkin-Elmer) and cloned into the PstI and HindIII sites of pQE31 (Qiagen). MTBP (pCEP-MTBP-HA) contains full length murine cDNA for MTBP excised from the pCR-XL-TOPO vector and cloned into the NotI site of pCEP (Invitrogen). p53 contains full length human p53 cloned into the pCEP vector. The p53 antibody Ab-1 (PAb421), the MDM2 antibody used for western blotting Ab-1 (IF2) and the anti-β-galactosidase antibody Ab-1 (200-193) were purchased from Oncogene Research Products. The MDM2 antibody used for immunoprecipitation, SMP14, and the antibody used to detect p21waf1/cip1 (F-5) were purchased from Santa Cruz Biotechnology, Inc. while the anti-Hemagglutinin A (HA) antibodies (12CA5 and 16BI2) used to detect HA-tagged MTBP were purchased from Roche Molecular Biologicals and BAbCO, respectively. The anti-CD20 antibody leu16 was purchased from Becton Dickinson-and the anti-mouse-IgG-FITC conjugate was obtained from Pierce.
    • Example 2 Yeast Two Hybrid Screen
  • The MATCHMAKER system (Clontech) was used to screen a mouse T-cell lymphoma library (ML4001AE) and to assess interactions between the GAL4-DBD-MTBP and GAL4-AD-MDM2 deletion mutants.
    • Example 3 Cloning and Analysis of MTBP
  • The Marathon RACE system (Clontech) was used to amplify the 5′ and 3′ ends of MTBP from a murine B cell cDNA. Total cellular RNA was prepared from murine SP2 (ATCC# CRL-1646) cells using RNAZOL (MBI) and poly A+ RNA was isolated from this using OLIGOTEX beads (Qiagen). 5-prime RACE was performed using the gene specific oligonucleotides GSP-1 (5′tga aga ata agg ttc aac tgt acc 3′ (SEQ ID NO:7)) and GSP-2 (5′cag ctt tca cgg tgt ctg ttt g 3′ (SEQ ID NO:8)). PCR was performed with rTth-XL and products were cloned into pCR2.1 (Invitrogen). 3-prime RACE was also performed and confirmed the termination codon identified in the yeast two hybrid screen. Sequencing was performed using dye terminators and an ABI-373 sequencer. Homology to BO11 and BO122 was identified using the FASTA program to examine the Saccharomyces cerevisiae database at Stanford University. The full length cDNA for MTBP was prepared by PCR amplification with the oligonucleotides MTBP-5′-NotI (5′ gag aga gcg gcc gcg gcg cga aga gga tgg atc ggt act tgc tg 3′ (SEQ ID NO:9)) and MTBP-3′-HA-NotI (5′gag aga gcg gcc gcc tac agg gag gcg taa tcg ggc aca tcg tag ggg tat ttc ttg ctc atc ttt tct acc acc 3′ (SEQ ID NO:10)) using rTth-XL and the product was cloned into PCR-XL-TOPO (Invitrogen).
    • Example 4 In vitro Binding and Immunoassays
  • For in vitro binding assays, MDM2 or Δ166-MDM2 were expressed in XL-1 bacteria (Stratagene) from the pQE32-MDM2 and pQE31-Δ166-MDM2 constructs, respectively, captured on Ni++-agarose (Qiagen) and washed with buffers B, C and D as described by the manufacturer. Prior to all binding reactions, protein captured onto beads was run on a SDS-polyacrylamide gel and analyzed by both western blotting and staining with coomassie blue. Washed beads (100 μl) were then mixed with 10 μl of in vitro translated protein (TNT, Promega) for 3 hours at 30° C., followed by washing three times in Dignam's buffer D supplemented with 75 mM imidazole (Dignam et al. Nucleic Acids Res. 1983 11:1475-1489). Beads were then resuspended in loading buffer and analyzed by SDS-PAGE and fluorography using AMPLIFY (Amersham Pharmacia).
  • Cells were transfected by either the calcium phosphate-DNA co-precipitation method (Sambrook et al. 1989 Molecular Cloning, A Laboratory Manual 2nd edition Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.) or by using FUGENE-6 (Roche) according to the manufacturer's instructions. For immunoprecipitation experiments cells were typically transfected with 10 μg of each plasmid and proteins were extracted 48-72 hours post transfection. Transfected cells were harvested and the cell pellet lysed in IP buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, 0.10-0 TRITON-X100, 0.5 mg/ml BSA) in the presence of the protease inhibitors: 1-2 μg/ml aprotinin, 1-2 μg/ml leupeptin, 1 μg/ml pepstatin A, 100 μg/ml soybean trypsin inhibitor (Roche) and 1 mM phenylmethylsulfonylfluoride, for 10 minutes, on ice. The lysate was clarified by centrifugation for 10 minutes at 4° C. and the concentration of total proteins determined by Bio-Rad Protein Assay (BioRad). Between 1 and 5 mg of protein was then pre-cleared by incubation with 50 μl of protein G-sepharose (Amersham Pharmacia) for 1 hour at 4° C. Pre-cleared lysate was incubated with 1 μg of primary antibody for 1 hour at 4° C., followed by incubation with 50 μl of protein G-sepharose for 2 hours at 4° C. Immunoprecipitated complexes were washed three times with IP buffer, resuspended in 30 μl of protein sample buffer (0.1 M Tris-HCl, pH 6-8, 4% SDS, 0.2% bromophenol blue, 20% glycerol, 0.5 M DTT) and subjected to SDS-PAGE followed by transfer to Hybond-ECL membrane (Amersham Pharmacia). Following incubation with primary antibodies and subsequently with anti-mouse-IgG-HRP (Amersham Pharmacia), the signal was detected by enhanced chemiluminescence with RENAISSANCE (NEN).
    • Example 5 FACS, Cell Cycle Analysis and Colony Assays
  • Saos-2 and U20S cells were transfected using FUGENE-6 with the indicated plasmids. Cells were harvested and analyzed by FACS essentially as described by Chen et al. Mol. Cell Biol. 1996 16:2445-2452. Briefly, nocodazole was added to the indicated cells at 50 ng/ml for 12 hours prior to harvesting. Cells were harvested 48-72 hours after the addition of FUGENE-DNA complexes and washed in Dulbecco's phosphate buffered saline containing 1% bovine serum albumin (PB). CD20 positive cells were detected using anti-CD20 antibody and an anti-mouse-IgG-FITC conjugate. Cells were fixed in ethanol and then stained in propidium iodide. Cells were analyzed using a FACSCAN (Becton Dickinson) and LYSIS-II software. H1299 cells were transtected using either the calcium phosphate precipitation method or FUGENE-6. Typically for the calcium phosphate precipitate procedure, 24 hours after removal of precipitates, hygromycin B (Roche) was added to a final concentration of 200 μg/ml. Cells were maintained under selective conditions for 72 hours, washed and refed with hygromycin-free complete media. Nocodazole (Sigma) was added as indicated at a concentration of 20 ng/ml, 16 hours before cells were harvested for analysis.
  • For colony formation assays, cells were transfected with the indicated plasmids and 24-48 hours after addition of DNA, hygromycin-B was added at a final concentration of 200 μg/ml. Cells were refed every three days with media containing Hygromycin-B until colonies were visible. For some experiments cells were stained with Giemsa.

Claims (10)

1. An isolated nucleic acid sequence encoding a mammalian MDM2 binding protein.
2. The isolated nucleic acid sequence of claim 1 comprising SEQ ID NO:1 or 3.
3. A vector comprising the isolated nucleic acid sequence of claim 1.
4. A host cell expressing the vector of claim 3.
5. An isolated polypeptide sequence of a mammalian MDM2 binding protein.
6. The isolated polypeptide sequence of claim 5 comprising SEQ ID NO:2 or 4.
7. An antibody targeted to the isolated polypeptide of claim 5.
8. A composition for modulating the G1 phase of cell cycling comprising a compound which alters levels or activity of a mammalian MDM2 binding protein.
9. The composition of claim 8 wherein the compound is an antisense agent targeted to a gene encoding a mammalian MDM2 binding protein, a ribozyme targeted to a gene encoding a mammalian MDM2 binding protein, a peptide mimic of a mammalian MDM2 binding protein or a modulator of MDM2 expression.
10. A method for modulating the G1 phase of cell cycling of cells comprising contacting cells with a composition of claim 8.
US10/312,954 2000-07-12 2001-07-12 Mammalian MDM2 binding proteins and uses thereof Expired - Fee Related US7166712B2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/312,954 US7166712B2 (en) 2000-07-12 2001-07-12 Mammalian MDM2 binding proteins and uses thereof
US11/650,159 US7304142B2 (en) 2000-07-12 2007-01-05 Mammalian MDM2 binding proteins
US11/876,901 US7732577B2 (en) 2000-07-12 2007-10-23 Isolated antibody specific for a mammalian MDM2 binding protein comprising SEQ ID No. 2 or 4
US12/759,906 US20100286362A1 (en) 2000-07-12 2010-04-14 Mammalian MDM2 Binding Proteins and Uses Thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21783500P 2000-07-12 2000-07-12
PCT/US2001/022053 WO2002004601A2 (en) 2000-07-12 2001-07-12 Mammalian mdm2 binding proteins and uses thereof
US10/312,954 US7166712B2 (en) 2000-07-12 2001-07-12 Mammalian MDM2 binding proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/650,159 Division US7304142B2 (en) 2000-07-12 2007-01-05 Mammalian MDM2 binding proteins

Publications (2)

Publication Number Publication Date
US20050277764A1 true US20050277764A1 (en) 2005-12-15
US7166712B2 US7166712B2 (en) 2007-01-23

Family

ID=35461370

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/312,954 Expired - Fee Related US7166712B2 (en) 2000-07-12 2001-07-12 Mammalian MDM2 binding proteins and uses thereof
US11/650,159 Expired - Fee Related US7304142B2 (en) 2000-07-12 2007-01-05 Mammalian MDM2 binding proteins
US11/876,901 Expired - Fee Related US7732577B2 (en) 2000-07-12 2007-10-23 Isolated antibody specific for a mammalian MDM2 binding protein comprising SEQ ID No. 2 or 4
US12/759,906 Abandoned US20100286362A1 (en) 2000-07-12 2010-04-14 Mammalian MDM2 Binding Proteins and Uses Thereof

Family Applications After (3)

Application Number Title Priority Date Filing Date
US11/650,159 Expired - Fee Related US7304142B2 (en) 2000-07-12 2007-01-05 Mammalian MDM2 binding proteins
US11/876,901 Expired - Fee Related US7732577B2 (en) 2000-07-12 2007-10-23 Isolated antibody specific for a mammalian MDM2 binding protein comprising SEQ ID No. 2 or 4
US12/759,906 Abandoned US20100286362A1 (en) 2000-07-12 2010-04-14 Mammalian MDM2 Binding Proteins and Uses Thereof

Country Status (1)

Country Link
US (4) US7166712B2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100168388A1 (en) * 2007-01-31 2010-07-01 Federico Bernal Stabilized p53 peptides and uses thereof
US8859723B2 (en) 2010-08-13 2014-10-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8927500B2 (en) 2012-02-15 2015-01-06 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US9096684B2 (en) 2011-10-18 2015-08-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10301351B2 (en) 2007-03-28 2019-05-28 President And Fellows Of Harvard College Stitched polypeptides
US10471120B2 (en) 2014-09-24 2019-11-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10905739B2 (en) 2014-09-24 2021-02-02 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166712B2 (en) * 2000-07-12 2007-01-23 Philadelphia, Health And Education Corporation Mammalian MDM2 binding proteins and uses thereof
WO2022240757A1 (en) 2021-05-10 2022-11-17 Entrada Therapeutics, Inc. Antigen-binding and antigen degradation constructs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083723A (en) * 1996-12-13 2000-07-04 Chiron Corporation Method for expression of heterologous proteins in yeast
US6204253B1 (en) * 1996-09-26 2001-03-20 Ludwig Institute For Cancer Research Factors which interact with oncoproteins
US6265165B1 (en) * 1998-11-12 2001-07-24 The Regents Of The University Of California Methods for EST-specific full length cDNA cloning
US6372490B1 (en) * 1999-02-23 2002-04-16 Curagen Corporation Nucleic acid encoding the MDM interacting protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69232722T2 (en) * 1991-08-23 2002-12-05 The Board Of Regents Of The University Of Nebraska, Lincoln METHOD AND COMPOSITIONS FOR CELLULAR REPROGRAMMING
IT1270662B (en) * 1994-10-13 1997-05-07 Applied Research Systems INTERLEUCHIN-1 ANTAGONIST
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
US7166712B2 (en) * 2000-07-12 2007-01-23 Philadelphia, Health And Education Corporation Mammalian MDM2 binding proteins and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204253B1 (en) * 1996-09-26 2001-03-20 Ludwig Institute For Cancer Research Factors which interact with oncoproteins
US6083723A (en) * 1996-12-13 2000-07-04 Chiron Corporation Method for expression of heterologous proteins in yeast
US6265165B1 (en) * 1998-11-12 2001-07-24 The Regents Of The University Of California Methods for EST-specific full length cDNA cloning
US6372490B1 (en) * 1999-02-23 2002-04-16 Curagen Corporation Nucleic acid encoding the MDM interacting protein

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
US20100168388A1 (en) * 2007-01-31 2010-07-01 Federico Bernal Stabilized p53 peptides and uses thereof
US9527896B2 (en) 2007-01-31 2016-12-27 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
US10202431B2 (en) 2007-01-31 2019-02-12 Aileron Therapeutics, Inc. Stabilized P53 peptides and uses thereof
US10301351B2 (en) 2007-03-28 2019-05-28 President And Fellows Of Harvard College Stitched polypeptides
US9957299B2 (en) 2010-08-13 2018-05-01 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8859723B2 (en) 2010-08-13 2014-10-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10308699B2 (en) 2011-10-18 2019-06-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9096684B2 (en) 2011-10-18 2015-08-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9522947B2 (en) 2011-10-18 2016-12-20 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10227380B2 (en) 2012-02-15 2019-03-12 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US10213477B2 (en) 2012-02-15 2019-02-26 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9505804B2 (en) 2012-02-15 2016-11-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US8927500B2 (en) 2012-02-15 2015-01-06 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9845287B2 (en) 2012-11-01 2017-12-19 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US9604919B2 (en) 2012-11-01 2017-03-28 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US10669230B2 (en) 2012-11-01 2020-06-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US10471120B2 (en) 2014-09-24 2019-11-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10905739B2 (en) 2014-09-24 2021-02-02 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1

Also Published As

Publication number Publication date
US7732577B2 (en) 2010-06-08
US20100286362A1 (en) 2010-11-11
US20090017538A1 (en) 2009-01-15
US7304142B2 (en) 2007-12-04
US20070129324A1 (en) 2007-06-07
US7166712B2 (en) 2007-01-23

Similar Documents

Publication Publication Date Title
US7304142B2 (en) Mammalian MDM2 binding proteins
Boyd et al. A novel cellular protein (MTBP) binds to MDM2 and induces a G1 arrest that is suppressed by MDM2
Mitsui et al. Involvement of Fes/Fps tyrosine kinase in semaphorin3A signaling
US5691179A (en) Cell death regulators
Li et al. A novel muscle-specific β1 integrin binding protein (MIBP) that modulates myogenic differentiation
US20080220455A1 (en) p53-DEPENDENT APOPTOSIS-INDUCING PROTEIN AND METHOD OF SCREENING FOR APOPTOSIS REGULATOR
US20080063638A1 (en) Mitotic kinesin-like protein-1, MKLP1, and uses therof priority
WO2006038208A2 (en) Agents capable of downregulating an msf-a - dependent hif-1α and use thereof in cancer treatment
EP1235934B1 (en) Screening method for candidate drugs
WO2001025427A1 (en) Shear stress-response dna
WO1999015662A1 (en) Telomere repeat binding factors and diagnostic and therapeutic use thereof
US20030092054A1 (en) Protein complexes and assays for screening anti-cancer agents
US7087386B2 (en) Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto
WO2002004601A2 (en) Mammalian mdm2 binding proteins and uses thereof
KR101083852B1 (en) A gene transcription regulator and a screening method for a compound inhibiting histone deacetylase
US20030138839A1 (en) Mammalian tumor susceptibility gene products and their uses
JP2005525087A (en) GIP, a family of polypeptides with transcription factor activity that interact with Goodpasture antigen binding proteins
US7569351B2 (en) P53 dependent apoptosis-associated gene and protein
US6361954B1 (en) Methods of immunoassay for human CDC6
US7348407B2 (en) Stress-responsive activator of p300 (strap) protein
JP4628674B2 (en) Methods of diagnosis and treatment and agents useful therefor
JP4522855B2 (en) GEF-H1b: biomarker, complex thereof, assay and therapeutic use
US7118886B1 (en) Ese genes and proteins
JP2004073142A (en) Ganp binding protein
US20050119456A1 (en) Protein that modulates the stability of transcriptional regulatory complexes regulating nuclear hormone receptor activity, dna encoding same, and antibodies thereto

Legal Events

Date Code Title Description
AS Assignment

Owner name: PHILADELPHIA, HEALTH AND EDUCATION CORPORATION, PE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOYD, MARK THOMAS;HAINES, DALE STEWART;VLATKOVIC, NIKOLINA;REEL/FRAME:015229/0024

Effective date: 20040413

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Expired due to failure to pay maintenance fee

Effective date: 20150123